SCHEMBL25307397

SCHEMBL25307397

CC(C)(C)OC(=O)CN1CCC(Oc2ccc([N+](=O)[O-])nc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
WNT1 P04628 1/20 0.39
GSK3B P49841 1/20 0.39
DYRK1A Q13627 1/20 0.39
GPR119 Q8TDV5 4/20 0.39
LIPE Q05469 1/20 0.38
CSF1R P07333 2/20 0.38
FLT3 P36888 2/20 0.38
PDGFRB P09619 1/20 0.38
KIT P10721 1/20 0.38
PDGFRA P16234 1/20 0.38
ALDH1A1 P00352 2/20 0.37
RECQL P46063 1/20 0.37
CYP4F2 P78329 1/20 0.36
CYP4A11 Q02928 1/20 0.36
CDK9 P50750 1/20 0.36
KDM4E B2RXH2 1/20 0.36
CNR1 P21554 1/20 0.36
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2488396 0.84 GPR119 (0.55) MAPTGPR119ALDH1A1
SCHEMBL25304402 0.83 DYRK1A (0.41) WNT1GSK3BDYRK1AGPR119LIPE
SCHEMBL17155001 0.78 SLC6A2 (0.47) MAPTALDH1A1KDM4ERAB9AL3MBTL1
SCHEMBL10256053 0.78 USP30 (0.42) MAPTGPR119ALDH1A1RAB9A
SCHEMBL30978672 0.78 USP30 (0.42) MAPTGPR119ALDH1A1RAB9A
SCHEMBL20758198 0.78 MAPT (0.49) MAPTRAB9A
SCHEMBL31726827 0.77 GPR119 (0.55) MAPTGPR119ALDH1A1
SCHEMBL28681114 0.77 CHEK2 (0.51) MAPTGPR119ALDH1A1CYP4F2CYP4A11
SCHEMBL28681115 0.77 CHEK2 (0.51) MAPTGPR119ALDH1A1CYP4F2CYP4A11
SCHEMBL30978676 0.76 MAPT (0.41) MAPTGPR119ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074891-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-03-06 US disclosed
EP-4452966-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 EP disclosed
WO-2023115149-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074891-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS MLKL, RIPK3, CASP9 MAPT 187/4885WNT1 1758/4885GSK3B 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.